• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Rostom, Y., Abdelmoneim, S., Farouk, M., Nabil, S., Fadhloon, N. (2022). OVERCOMING MULTIDRUG RESISTANCE OF TRIPLE NEGATIVE BREAST CANCER CELL LINE USING miRNA 374C-5PCHITOSAN NANOPARTICLE CONJUGATES. ALEXMED ePosters, 4(1), 52-53. doi: 10.21608/alexpo.2022.127807.1385
Yousri Rostom; Salah El-Din Abdelmoneim; Mohamed Farouk; Samar Nabil; Noor Fadhloon. "OVERCOMING MULTIDRUG RESISTANCE OF TRIPLE NEGATIVE BREAST CANCER CELL LINE USING miRNA 374C-5PCHITOSAN NANOPARTICLE CONJUGATES". ALEXMED ePosters, 4, 1, 2022, 52-53. doi: 10.21608/alexpo.2022.127807.1385
Rostom, Y., Abdelmoneim, S., Farouk, M., Nabil, S., Fadhloon, N. (2022). 'OVERCOMING MULTIDRUG RESISTANCE OF TRIPLE NEGATIVE BREAST CANCER CELL LINE USING miRNA 374C-5PCHITOSAN NANOPARTICLE CONJUGATES', ALEXMED ePosters, 4(1), pp. 52-53. doi: 10.21608/alexpo.2022.127807.1385
Rostom, Y., Abdelmoneim, S., Farouk, M., Nabil, S., Fadhloon, N. OVERCOMING MULTIDRUG RESISTANCE OF TRIPLE NEGATIVE BREAST CANCER CELL LINE USING miRNA 374C-5PCHITOSAN NANOPARTICLE CONJUGATES. ALEXMED ePosters, 2022; 4(1): 52-53. doi: 10.21608/alexpo.2022.127807.1385

OVERCOMING MULTIDRUG RESISTANCE OF TRIPLE NEGATIVE BREAST CANCER CELL LINE USING miRNA 374C-5PCHITOSAN NANOPARTICLE CONJUGATES

Article 1, Volume 4, Issue 1, March 2022, Page 52-53  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.127807.1385
View on SCiNiTO View on SCiNiTO
Authors
Yousri Rostom1; Salah El-Din Abdelmoneim1; Mohamed Farouk1; Samar Nabil2; Noor Fadhloon email 1
1Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University
2Department of Pathology, Faculty of Medicine, Alexandria University
Abstract
Breast cancer is considered the 2nd highest in incidence at 17.9% accounting for 38.8% of all the female cases of cancers recorded in Egypt and the 2ndleading cause of death at 10.8%.
Amongst the molecular subtypes of breast cancer, Triple negative breast cancer (TNBC) is marked as the most aggressive. It constitutes 15-20% of breast cancers. It is associated with earlier age of onset, aggressive clinical course, and dismal prognosis.
Although strategies targeting breast cancer have already been improved, systemic treatments to guard against metastasis are less effective. It is therefore essential to develop novel therapeutics for the control of breast cancer initiation and progression.
The emergence of non-coding RNAs (ncRNAs) as crucial regulators of gene expression has raised exciting possibilities towards them being explored as alternative therapeutics for the management of various pathological conditions including breast cancer.
To find a safe and efficient non-viral vector for miRNA delivery, we investigated the interaction between chitosans and miRNA374C-5P and the influence of the resulting CS–miRNA complexes on the uptake of miRNA into triple negative breast cancer lines (MDA-MB-231).
Keywords
miRNA374C-5P; chitosan nanoparticles; Triple negative breast cancer (TNBC)
Statistics
Article View: 133
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.